Concepedia

Publication | Open Access

MEVITEM—a phase I/II trial of vismodegib + temozolomide vs temozolomide in patients with recurrent/refractory medulloblastoma with Sonic Hedgehog pathway activation

DOIFull Paper Access

32

Citations

40

References

2021

Year

Didier Frappaz, Marc Barritault, Laure Montané, Florence Laigle–Donadey, Olivier Chinot, Émilie Le Rhun, Alice Bonneville-Levard, Andreas F. Hottinger, David Meyronnet, Anne-Sophie Bidaux,
Neuro-Oncology

Abstract

The addition of vismodegib to TMZ did not add toxicity but failed to improve PFS-6 in SHH recurrent/refractory medulloblastoma. Prediction of sensitivity to vismodegib needs further refinements.

References

YearCitations

Page 1